Retraction Casts Doubt on Timing Effects of Immunotherapy.

Published in

Cancer discovery. Pages OF1. Jul 09, 2026. Epub Jul 09, 2026.

Abstract

A discredited trial has fractured trust in one landmark result-the first randomized evidence on checkpoint inhibitor dosing timing-but not the broader hypothesis it was meant to prove: that circadian biology shapes immunotherapy efficacy. Researchers on both sides of the debate are now recalculating what the surviving evidence can actually support.

PMID:
42423479
Bibliographic data and abstract were imported from PubMed on 09 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.